Overview
T-cell lymphoma (TCL) encompasses a heterogeneous group of malignancies arising from T-lymphocytes, presenting significant therapeutic challenges due to variable prognoses and responses to treatment 1.Diagnosis
Immunophenotyping: Essential using monoclonal antibodies like UCHL1 and MT1 for reliable T-cell marker identification 6.
Cytogenetic Analysis: Clonal chromosome abnormalities are common and can guide subclassification 5.
HTLV-1 Serology: Particularly relevant in certain geographic regions to differentiate virus-associated from virus-negative T-cell lymphomas 7.
Histopathological Evaluation: Subclassification based on morphological features, including pleomorphic and anaplastic large cell types 7.Management
First-Line Treatments: Not explicitly detailed in abstracts; typically includes chemotherapy regimens tailored to subtype 23.
Allogeneic Stem Cell Transplantation (alloSCT): Indicated for relapsed/refractory disease or post-autologous transplant failure; myeloablative conditioning used in 55% of cases 1.
Adjunctive Therapies: Specific drug classes and doses not detailed; management often involves multidisciplinary approaches 23.
Management of Complications: Aggressive management of acute spontaneous tumor lysis syndrome, including continuous renal replacement therapy in cases of hyperuricemic acute renal failure 4.Special Populations
Pregnancy: Not addressed in provided abstracts.
Pediatrics: Not addressed in provided abstracts.
Elderly: Not specifically discussed in terms of tailored management approaches.
Comorbidities: Management considerations for comorbidities like renal failure highlighted in specific cases 4.Key Recommendations
Consider Allogeneic Stem Cell Transplantation for Relapsed/Refractory T-Cell Lymphoma: Offers durable remission with overall survival rates of 51% at 5 years (Evidence: Strong 1).
Utilize Comprehensive Immunophenotyping for Accurate Diagnosis: Employ reliable markers such as UCHL1 and MT1 for T-cell identification (Evidence: Moderate 6).
Screen for HTLV-1 Seropositivity in Appropriate Populations: Differentiates virus-associated from non-associated T-cell lymphomas, particularly relevant in endemic regions (Evidence: Moderate 7).References
1 Singh V, Kim S, Deol A, Uberti JP, Modi D. Allogeneic hematopoietic stem cell transplantation in T-cell lymphoma: a Meta-Analysis. Leukemia & lymphoma 2022. link
2 . Recent advances in the treatment of T-cell lymphomas. Clinical advances in hematology & oncology : H&O 2010. link
3 . New strategies in the treatment of T-cell lymphoma. Clinical advances in hematology & oncology : H&O 2008. link
4 Hsu HH, Huang CC. Acute spontaneous tumor lysis in anaplastic large T-cell lymphoma presenting with hyperuricemic acute renal failure. International journal of hematology 2004. link
5 Mecucci C, Louwagie A, Thomas J, Boogaerts M, Van Den Berghe H. Cytogenetic studies in T-cell malignancies. Cancer genetics and cytogenetics 1988. link90093-3)
6 Norton AJ, Isaacson PG. An immunocytochemical study of T-cell lymphomas using monoclonal and polyclonal antibodies effective in routinely fixed wax embedded tissues. Histopathology 1986. link
7 Lennert K, Kikuchi M, Sato E, Suchi T, Stansfeld AG, Feller AC et al.. HTLV-positive and -negative T-cell lymphomas. Morphological and immunohistochemical differences between European and HTLV-positive Japanese T-cell lymphomas. International journal of cancer 1985. link
8 Kittas C, Hansmann ML, Borisch B, Feller AC, Lennert K. The blood microvasculature in T-cell lymphomas. A morphological, ultrastructural and immunohistochemical study. Virchows Archiv. A, Pathological anatomy and histopathology 1985. link